Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Sequential RCHOP, Radioimmunotherapy and Rituximab Maintenance Improves Early Outcomes in Advanced Stage Follicular Lymphoma: 5 Year Outcomes from SWOG 0801

Paul M. Barr, Hongli Li, PhD, Richard Burack, MD PhD, Michael LeBlanc, PhD, Sonali M. Smith, MD, Ajay K. Gopal, MD, Justin D. Floyd, DO, Daniel O. Persky, MD, Oliver Press, MD PhD, Richard I. Fisher, MD, Jonathan W. Friedberg, MD

Blood (2016) 128 (22): 614.

https://doi.org/10.1182/blood.V128.22.614.614

Published: 2016

Journal Articles

Continued Excellent Outcomes in Previously Untreated Follicular Lymphoma Patients after Treatment with CHOP Plus Rituximab or CHOP Plus (131) Iodine-Tositumomab - Long Term Follow-up of Phase III Randomized Study SWOG S0016

Mazyar Shadman, MD MPH, Hongli Li, PhD, Lisa Rimsza, MD, John P. Leonard, MD, Mark S Kaminski, MD, Rita M Braziel, MD, Catherine M. Spier, MD, Ajay K Gopal, MD, David G Maloney, MD PhD, Bruce Cheson, MD, Shaker Dakhil, MD FACP, Michael LeBlanc, PhD, Sonali M. Smith, MD, Richard I. Fisher, MD, Jonathan W. Friedberg, MD, Oliver Press, MD PhD

Blood (2016) 128 (22): 616.

https://doi.org/10.1182/blood.V128.22.616.616

Published: 2016

Journal Articles

Autologous Transplantation As Consolidation for High Risk Aggressive T-Cell Non-Hodgkin's Lymphoma: A SWOG S9704 Intergroup Trial Subgroup Analysis

Blood (2016) 128 (22): 4651.

https://doi.org/10.1182/blood.V128.22.4651.4651

Published: 2016

Journal Articles

Genomic Alterations Important for the Prognosis in Patients with Follicular Lymphoma Treated on SWOG Study S0016

Xiaoyu Qu, PhD, Hongli Li, PhD, Oliver W Press, MD PhD, Lisa M. Rimsza, MD, Rita M. Braziel, MD, Michael Leblanc, PhD, Eric D. Hsi, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD MMSc, Min Fang, MD PhD

Blood (2015) 126 (23): 2678.

https://doi.org/10.1182/blood.V126.23.2678.2678

Published: 2015

Journal Articles

Pre-Transplant R-Bendamustine Induces High Rates of Minimial Residual Disease in MCL Patients: Updated Results of S1106: US Intergroup Study of a Randomized Phase II Trial of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplants for Patients with Mantle Cell Lymphoma

Blood (2015) 126 (23): 518.

https://doi.org/10.1182/blood.V126.23.518.518

Published: 2015

Journal Articles

A Phase I/II Trial of Vorinostat (SAHA) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG S0806

Daniel O. Persky, MD, Hongli Li, PhD, Lisa M. Rimsza, MD, Paul M. Barr, MD, Leslie L. Popplewell, MD, Charles L. Bane, MD, Ann Von Gehr, MD, Michael Leblanc, PhD, Richard I. Fisher, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD MMSc

Blood (2015) 126 (23): 3931.

https://doi.org/10.1182/blood.V126.23.3931.3931

Published: 2015

Journal Articles

SWOG S0410/BMT CTN 0703: A Phase II Trial of Tandem Autologous Stem Cell Transplantation (AHCT) for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma (HL) (ClinicalTrials.gov Identifier: NCT00233987)

Eileen P. Smith, MD, Hongli Li, M.S., Jonathan W. Friedberg, MD, Louis Constine, MD, Lisa M. Rimsza, MD, Ginna G. Laport, MD, Leslie L. Popplewell, MD, David G Maloney, MDPhD, Michael Leblanc, PhD, Stephen J. Forman, MD, Richard I. Fisher, MD, Patrick J. Stiff, MD

Blood (2014) 124 (21): 676.

https://doi.org/10.1182/blood.V124.21.676.676

Published: 2014

Journal Articles

Long Term Follow up of SWOG S0313: Ibritumomab Tiuxetan Consolidation after 3 Cycles of CHOP Plus Radiotherapy for High Risk Limited Stage Aggressive B-Cell Lymphoma

Daniel O Persky, MD, Thomas P. Miller, MD, Joseph M Unger, PhD, Catherine M. Spier, MD, Soham D. Puvvada, MD, B. Dino Stea, MDPhD, Oliver W. Press, MD PhD, Louis Constine, MD, Kevin Barton, MD, Michael LeBlanc, PhD, Sonali Smith, MD, Richard I. Fisher, MD, Jonathan W. Friedberg, MD

Blood (2014) 124 (21): 4414.

https://doi.org/10.1182/blood.V124.21.4414.4414

Published: 2014

Journal Articles

Phase II Trial of R-CHOP Plus Bortezomib Induction Therapy Followed By Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601

Brian G. Till, MD, Hongli Li, M.S., Steven H. Bernstein, MD, Richard I. Fisher, MD, Richard Burack, MDPhD, Lisa M. Rimsza, MD, Justin Floyd, DO, Marco A. DaSilva, MD, Dennis F. Moore, MD, Michael LeBlanc, PhD, Jonathan W. Friedberg, MD

Blood (2014) 124 (21): 149.

https://doi.org/10.1182/blood.V124.21.149.149

Published: 2014

Journal Articles

MYC Associated and Double Protein Lymphoma: Subset Analysis of SWOG S9704

Soham D. Puvvada, MD, Patrick J Stiff, MD, Michael Leblanc, PhD, James R. Cook, MD PhD, Brad Kahl, MD, Hongli Li, M.S., Lisa M. Rimsza, MD, Jonathan W. Friedberg, MD, Sonali M. Smith, MD

Blood (2014) 124 (21): 1710.

https://doi.org/10.1182/blood.V124.21.1710.1710

Published: 2014

Journal Articles

MYC Protein Expression, but Not High Grade Morphology, Is Associated with Poor Outcome in Non-Burkitt Diffuse Aggressive B-Cell Lymphomas: A SWOG S9704 Correlative Study

James R. Cook, MD, PhD, Bryan H. Goldman, MS, Raymond R. Tubbs, DO, Michael LeBlanc, PhD, Lisa M. Rimsza, MD, Patrick Stiff, MD, Richard I Fisher, MD

Blood (2012) 120 (21): 543.

https://doi.org/10.1182/blood.V120.21.543.543

Published: 2012

Journal Articles

Low Serum Vitamin D Levels Are Associated with Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and Lysa Studies.

Jennifer L. Kelly, PhD, MPH, Gilles Salles, MD, Bryan H. Goldman, MS, Richard I Fisher, MD, Olivier Casasnovas, Oliver W. Press, MD, PhD, David G. Maloney, MD, PhD, Pierre Soubeyran, Lisa M. Rimsza, MD, Michael LeBlanc, PhD, Herve Tilly, MD, Jonathan W. Friedberg, MD

Blood (2012) 120 (21): 2712.

https://doi.org/10.1182/blood.V120.21.2712.2712

Published: 2012

Journal Articles

Fc Gamma Receptor 3a Genotype Predicts Overall Survival for Follicular Lymphoma Patients Treated On Southwest Oncology Group Trials with Combined Monoclonal Antibody Plus Chemotherapy but Not Chemotherapy Alone.

Daniel O. Persky, MD, David Dornan, Ph.D, Bryan H Goldman, MS, Rita M. Braziel, MD, Richard I Fisher, MD, Michael LeBlanc, PhD, David G. Maloney, MD, PhD, Thomas P. Miller, MD, Oliver W. Press, MD, PhD, Lisa M. Rimsza, MD

Blood (2009) 114 (22): 111.

https://doi.org/10.1182/blood.V114.22.111.111

Published: 2009

Journal Articles

Effect of Adding Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy Consolidation to Three Cycles of CHOP Plus Involved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG 0313)

Thomas P. Miller, MD, Joseph M Unger, MS, Catherine Spier, MD, Baldassarre Stea, MD, PhD, Oliver W. Press, MD, PhD, Jonathan W. Friedberg, MD, Michael LeBlanc, PhD, Richard I Fisher, MD

Blood (2008) 112 (11): 3598.

https://doi.org/10.1182/blood.V112.11.3598.3598

Published: 2008

Journal Articles

A Multi Center Trial of hyperCVAD+Rituxan in Patients with Newly Diagnosed Mantle Cell Lymphoma.

Elliot M. Epner, MD, PhD, Joseph Unger, PhD, Thomas Miller, MD, Lisa Rimzsa, PhD, Catherine Spier, MD, Michael Leblanc, PhD, Richard Fisher, MD

Blood (2007) 110 (11): 387.

https://doi.org/10.1182/blood.V110.11.387.387

Published: 2007

Journal Articles

An Update of a Phase II Trial of CHOP Followed by Tositumomab/Iodine I-131 Tositumomab (Bexxar®) for Front-Line Treatment of Advanced Stage, Follicular Lymphoma: Southwest Oncology Group Protocol 9911.

Oliver W. Press, MD, PhD, Joseph Unger, David Maloney, MD, PhD, Rita M. Braziel, MD, Michael LeBlanc, PhD, Thomas Grogan, MD, Thomas P. Miller, MD, Richard I. Fisher, MD

Blood (2005) 106 (11): 352.

https://doi.org/10.1182/blood.V106.11.352.352

Published: 2005

Journal Articles

Extreme Regression: A Statistical Technique for Finding Good or Poor Prognostic Groups, Illustrated Using Myeloma Patient Data from Intergroup Trial S9321.

John J. Crowley, PhD, Jason McCoy, MS, Michael LeBlanc, PhD, Bart Barlogie, MD, PhD

Blood (2004) 104 (11): 5202.

https://doi.org/10.1182/blood.V104.11.5202.5202

Published: 2004

Journal Articles

Effect of Adding Rituximab to Three Cycles of CHOP Plus Invoved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG-0014).

Thomas P. Miller, MD, Joseph M. Unger, MS, Catherine Spier, MD, Baldassarre Stea, MD, PhD, Emilia Cantu, BA, Michael LeBlanc, PhD, Richard I. Fisher, MD

Blood (2004) 104 (11): 158.

https://doi.org/10.1182/blood.V104.11.158.158

Published: 2004

Journal Articles

Fc γ Receptor Polymorphisms Do Not Influence Progression Free Survival (PFS) of Follicular NHL Pateints Treated with Chop Followed by Rituximab (SWOG 9800).

David G. Maloney, MD, PhD, Barbara Pender-Smith, MS, Joseph M. Unger, MS, Rita M. Braziel, MD, Jerald Radich, MD, Oliver W. Press, MD, PhD, Thomas P. Miller, MD, Thomas M. Grogan, MD, Michael LeBlanc, PhD, Richard I. Fisher, MD

Blood (2004) 104 (11): 589.

https://doi.org/10.1182/blood.V104.11.589.589

Published: 2004

Journal Articles

Histologic Subtypes Do Not Confer Unique Outcomes in Early-Stage Lymphoma: Long-Term Follow-Up of SWOG 8736.

Catherine M. Spier, MD, Michael LeBlanc, PhD, Ellen M. Chase, BS, Richard I. Fisher, MD, Thomas P. Miller, MD

Blood (2004) 104 (11): 3263.

https://doi.org/10.1182/blood.V104.11.3263.3263

Published: 2004

NARROW

Sequential RCHOP, Radioimmunotherapy and Rituximab Maintenance Improves Early Outcomes in Advanced Stage Follicular Lymphoma: 5 Year Outcomes from SWOG 0801

Continued Excellent Outcomes in Previously Untreated Follicular Lymphoma Patients after Treatment with CHOP Plus Rituximab or CHOP Plus (131) Iodine-Tositumomab - Long Term Follow-up of Phase III Randomized Study SWOG S0016

Autologous Transplantation As Consolidation for High Risk Aggressive T-Cell Non-Hodgkin's Lymphoma: A SWOG S9704 Intergroup Trial Subgroup Analysis

Genomic Alterations Important for the Prognosis in Patients with Follicular Lymphoma Treated on SWOG Study S0016

Pre-Transplant R-Bendamustine Induces High Rates of Minimial Residual Disease in MCL Patients: Updated Results of S1106: US Intergroup Study of a Randomized Phase II Trial of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplants for Patients with Mantle Cell Lymphoma

A Phase I/II Trial of Vorinostat (SAHA) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG S0806

SWOG S0410/BMT CTN 0703: A Phase II Trial of Tandem Autologous Stem Cell Transplantation (AHCT) for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma (HL) (ClinicalTrials.gov Identifier: NCT00233987)

Long Term Follow up of SWOG S0313: Ibritumomab Tiuxetan Consolidation after 3 Cycles of CHOP Plus Radiotherapy for High Risk Limited Stage Aggressive B-Cell Lymphoma

Phase II Trial of R-CHOP Plus Bortezomib Induction Therapy Followed By Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601

MYC Associated and Double Protein Lymphoma: Subset Analysis of SWOG S9704

MYC Protein Expression, but Not High Grade Morphology, Is Associated with Poor Outcome in Non-Burkitt Diffuse Aggressive B-Cell Lymphomas: A SWOG S9704 Correlative Study

Low Serum Vitamin D Levels Are Associated with Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and Lysa Studies.

Fc Gamma Receptor 3a Genotype Predicts Overall Survival for Follicular Lymphoma Patients Treated On Southwest Oncology Group Trials with Combined Monoclonal Antibody Plus Chemotherapy but Not Chemotherapy Alone.

Effect of Adding Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy Consolidation to Three Cycles of CHOP Plus Involved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG 0313)

A Multi Center Trial of hyperCVAD+Rituxan in Patients with Newly Diagnosed Mantle Cell Lymphoma.

An Update of a Phase II Trial of CHOP Followed by Tositumomab/Iodine I-131 Tositumomab (Bexxar®) for Front-Line Treatment of Advanced Stage, Follicular Lymphoma: Southwest Oncology Group Protocol 9911.

Extreme Regression: A Statistical Technique for Finding Good or Poor Prognostic Groups, Illustrated Using Myeloma Patient Data from Intergroup Trial S9321.

Effect of Adding Rituximab to Three Cycles of CHOP Plus Invoved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG-0014).

Fc γ Receptor Polymorphisms Do Not Influence Progression Free Survival (PFS) of Follicular NHL Pateints Treated with Chop Followed by Rituximab (SWOG 9800).

Histologic Subtypes Do Not Confer Unique Outcomes in Early-Stage Lymphoma: Long-Term Follow-Up of SWOG 8736.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only